All conditions

Myasthenia Gravis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

289
Trials on record
83
Recruiting now
8
Australian sites
23
Phase 3 trials
3
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Myasthenia Gravis →

Get alerts when Myasthenia Gravis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Myasthenia Gravis

Myasthenia Gravis (MG) is a condition that affects the way messages travel between your nerves and muscles. In a healthy body, nerves send signals to muscles to tell them to move. In MG, the immune system mistakenly produces antibodies that block or damage the connection points where those signals are received. This means the muscles don't respond as well as they should, leading to weakness and fatigue that often gets worse with activity and improves with rest. The muscles most commonly affected include those controlling the eyes and eyelids, swallowing, speech, and limb strength, though this varies from person to person.

MG is considered a rare condition, but it is the most common disorder of the nerve-muscle connection. In Australia, it is estimated to affect roughly 1 in 10,000 people. It can occur at any age and in any gender, though it tends to appear in women under 40 and men over 60 most frequently. Having MG does not mean a person's intelligence, sensation, or general organ function is affected — the condition is specifically about muscle control.

Treatment in Australia is generally overseen by a neurologist, and the goal is typically to reduce symptoms and help people manage daily life as comfortably as possible. Approaches can include medications that improve nerve-to-muscle signalling, medications that calm the immune system's activity, and in some cases procedures or surgery depending on the individual's circumstances. Many people with MG are able to lead active, fulfilling lives with appropriate medical support. Your treating team is the best source of guidance about what options make sense for your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Myasthenia Gravis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Myasthenia Gravis

3 medicines listed on the PBS for Myasthenia Gravis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 3 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Ravulizumab Ultomiris Acute severe generalised myasthenia gravis (gMG) AU$6574.12 Authority required
Rozanolixizumab Rystiggo Acute severe generalised myasthenia gravis (gMG) AU$12177.2 Authority required
Zilucoplan Zilbrysq Acute severe generalised myasthenia gravis (gMG) AU$21395.05 Authority required
Ravulizumab Ultomiris Bridging therapy for generalised myasthenia gravis (gMG) AU$6574.12 Authority required
Rozanolixizumab Rystiggo Bridging therapy for generalised myasthenia gravis (gMG) AU$12177.2 Authority required
Zilucoplan Zilbrysq Bridging therapy for generalised myasthenia gravis (gMG) AU$21395.05 Authority required
Ravulizumab Ultomiris Treatment refractory generalised myasthenia gravis (gMG) AU$6574.12 Authority required
Rozanolixizumab Rystiggo Treatment refractory generalised myasthenia gravis (gMG) AU$12177.2 Authority required
Zilucoplan Zilbrysq Treatment refractory generalised myasthenia gravis (gMG) AU$21395.05 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Myasthenia Gravis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Myasthenia Gravis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Myasthenia Gravis by country. Australia is highlighted.

Showing the top 10 of 40 countries with trial sites.

Clinical trials for Myasthenia Gravis

Showing 87 of 87 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00294658 · University of Alabama at Birmingham Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 1 November 2015
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇩🇪 DE🇮🇹 IT🇯🇵 JP +10 more

Who might be able to join this trial: - You are male or female, aged between 18 and 65 years, and have been diagnosed with Myasthenia Gravis (MG), a condition that causes muscle weakness - Your MG has spread beyond just your eyes to affect other parts of your body, and this started within the last 5 years - A blood tes...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01997229 · Alexion Pharmaceuticals, Inc. Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 1 February 2016
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇮 FI +13 more

**Who might be able to join this trial:** - You are 18 years old or older (male or female) - You have been diagnosed with Myasthenia Gravis (MG), confirmed by a blood test showing specific antibodies (anti-AChR), plus at least one other test or sign of the condition, such as a nerve/muscle function test, a medication...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04951622 · Janssen Research & Development, LLC Phase 3 · 17 countries Recruiting
Recruiting Phase 3 Est. completion 17 November 2023
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE +9 more

**Who might be able to join this trial:** - You have been diagnosed with myasthenia gravis (MG) that affects muscles throughout your body, and your condition falls into a moderate-to-severe category based on a standard medical classification system - Your MG symptoms are significantly affecting your daily life, scorin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06193889 · Kyverna Therapeutics Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇦🇺 AU🇧🇷 BR🇩🇪 DE🇸🇦 SA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Your blood tests show specific antibodies linked to myasthenia gravis (called AChR or MuSK antibodies) - Your myasthenia gravis has been rated as moderate to severe by your doctor (classified as MGFA Class II–IV) - Your symptoms score at least 6 out of 24 on a standard daily...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06456580 · Vor Biopharma Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 1 May 2027
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR +6 more

**Who might be able to join this trial:** - You are 18 years old or older - You have already been diagnosed with generalized Myasthenia Gravis (MG), a condition that causes widespread muscle weakness affecting more than just the eyes - A blood test has confirmed you have specific antibodies (AChR or MuSK) linked to MG...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06463587 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA,... Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 23 August 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇳 CN🇫🇷 FR🇬🇪 GE +16 more

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have been diagnosed with Myasthenia Gravis (MG) with generalised muscle weakness, falling within a moderate-to-severe range of the condition (MGFA Class II to IVa), whether or not you test positive f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06517758 · Novartis Pharmaceuticals Phase 3 · 18 countries Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

**Who might be able to join this trial:** - You are between 18 and 85 years old and have been diagnosed with generalized Myasthenia Gravis (gMG) - A blood test has confirmed you have a specific antibody associated with Myasthenia Gravis (called AChR+ antibody) - Your Myasthenia Gravis is at a moderate to severe level,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06744920 · Novartis Pharmaceuticals Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 25 February 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇬🇪 GE +12 more

**Who might be able to join this trial:** - Adults between 18 and 75 years old who have been diagnosed with generalized Myasthenia Gravis (a muscle weakness condition that affects more than just the eyes) - People whose Myasthenia Gravis has been confirmed to be at a moderate to severe level (but not severe enough to n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07304154 · Kite, A Gilead Company Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 June 2029
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** **For Multiple Sclerosis (MS):** - You have been diagnosed with MS (any form, including relapsing or progressive) using recognised medical guidelines (2017 McDonald criteria) - For relapsing forms of MS: your MS has continued to be active despite being on a strong MS treatment...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07501702 · Vertex Pharmaceuticals Incorporated Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 2 March 2029
🇦🇺 AU🇵🇱 PL🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are between 18 and 80 years old - You have been diagnosed with generalized myasthenia gravis with widespread muscle weakness that fits a certain level of severity (known as MGFA classification II-IV — confirm with trial site) - There may be additional requirements set out in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04963270 · Hoffmann-La Roche Phase 3 · 17 countries Terminated
Terminated Phase 3 Est. completion 29 January 2024
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE +9 more

Who might be able to join this trial: - You have agreed to take part and signed a consent form (for teenagers, a parent or guardian must also sign, and the young person must agree to join) - You are able to follow the study schedule and procedures - You have been diagnosed with a type of myasthenia gravis (MG) confirme...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07125105 · Universite du Littoral Cote d'Opale Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 30 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with myasthenia gravis (in any form) by a neurologist. - You are being cared for at Lille University Hospital or one of its partner services, or at Amiens University Hospital. - Your medical team has confirmed you have no major reasons why adapted phys...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03792659 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - You are an adult who has been diagnosed with Myasthenia Gravis and are visiting the Yale Department of Neurology for either treatment or research purposes. Who may not be able to join: - Anyone who does not meet the inclusion criteria listed above would not be eligible to partic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04182984 · Tang-Du Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 19 and 74 years old - You have been diagnosed with Myasthenia Gravis (MG) that affects only the eye muscles (causing drooping eyelids or double vision, but no other symptoms), and you have never received treatment for it - Your diagnosis is supported by at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04202341 · Alexion Pharmaceuticals, Inc. Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇦🇹 AT🇨🇦 CA🇨🇳 CN🇩🇪 DE🇮🇹 IT🇸🇦 SA🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a form of Myasthenia Gravis called generalized Myasthenia Gravis (gMG) and are currently being treated with, or have previously been treated with, an Alexion C5 inhibitor therapy (such as Soliris or Ultomiris), even if you have since stopped that trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04535843 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have muscle weakness that comes and goes, along with tiredness in your muscles, plus at least one of the following: - A specific nerve test (called repetitive nerve stimulation) shows your muscles are responding in a particular abnormal way (confirm with trial site) - A b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04833894 · argenx Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇬🇪 GE🇩🇪 DE🇮🇹 IT🇳🇱 NL +4 more

**Who might be able to join this trial:** - The participant (and/or their legal guardian) must be able to understand the trial requirements, provide written agreement to take part, and be willing and able to attend all required visits and follow the trial procedures. - Children and teenagers aged 2 to under 18 years o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04837625 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have a medical history showing muscle weakness that comes and goes, along with a tendency to tire easily - Your blood tests have come back positive for certain proteins (called AChR or MuSK antibodies) that are linked to myasthenia gravis (MG) - If those blood tests were...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05067348 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Myasthenia Gravis (MG) and have a specific type of antibody in your blood called anti-AChR antibody - Your MG symptoms fall into a moderate-to-severe category based on a standard medical classification system (Class II, III, or IV — confirm with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05214612 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇪🇬 EG

**Who might be able to join this trial:** - You are 16 years old or older - You are any gender — both males and females are welcome - You have been diagnosed with Myasthenia Gravis (MG), a condition that causes muscle weakness, supported by at least one of the following: your symptoms clearly improved when taking a med...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05265273 · Janssen Research & Development, LLC Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 26 June 2026
🇯🇵 JP🇳🇱 NL🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - You are between 8 and under 18 years old (for US locations only) - You have been diagnosed with myasthenia gravis (MG) that affects muscles throughout your body, rated at a moderate to severe level based on a standard medical classification system - A blood test has shown yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05337891 · Jagiellonian University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇵🇱 PL

Who might be able to join this trial: - You have been suspected of having or have been diagnosed with myasthenia gravis (a condition that causes muscle weakness), whether it affects only your eyes or your whole body - You have already had, or are planned to have, blood tests to check for specific antibodies linked to m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05564936 · Ad scientiam Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 24 September 2025
🇫🇷 FR🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with generalized Myasthenia Gravis (gMG) with widespread muscle weakness of a certain level of severity, and you are not expected to need a breathing machine during the study - You have had a blood test that came back...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05868837 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 July 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have tested positive for specific antibodies linked to Myasthenia Gravis (MG) — called anti-AChR or anti-MuSK antibodies — confirmed through blood tests at the start of the study. - People who have at least one of the following in their medical history: abnormal n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06006832 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - You visited the neurology outpatient department at Peking Union Medical College Hospital (PUMCH) between September 30, 2022 and September 30, 2024. - You have been diagnosed with myasthenia gravis. - You have been followed up and monitored at PUMCH for more than 6 months. - You h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06055959 · UCB Biopharma SRL Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 16 November 2026
🇮🇹 IT🇵🇱 PL🇰🇷 KR🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - In the USA: you must be between 12 and 17 years old when you sign the consent form; in most other countries, children aged 2 to 17 years old may be eligible - You have been diagnosed with generalized myasthenia gravis (a muscle weakness condition), confirmed by a blood test...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06064461 · Vitaccess Ltd Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2034
🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with myasthenia gravis (a condition that causes muscle weakness) by a doctor. - You live in one of the countries covered by this study (confirm with trial site for the full list of countries). - You have access to a smartphone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06064695 · University of Missouri-Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇺🇸 US

**For People with Myasthenia Gravis (MG):** Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with Generalized Myasthenia Gravis (gMG), either through a positive blood test for certain antibodies or through clinical symptoms if the blood test was negative - You have been o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06220201 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 15 July 2027
🇧🇪 BE🇫🇷 FR🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** **Group 1 – Relapsing Multiple Sclerosis (MS):** - You have a relapsing form of MS with a disability level score between 3.0 and 5.5 on a standard MS scale (confirm with trial site) - Your MS has gotten worse within the last 12 months even while taking a strong MS medication f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06241521 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2034
🇨🇳 CN

**Who might be able to join this trial:** - You have muscle weakness that comes and goes, affecting muscles such as those controlling your eyes, swallowing, speaking, or moving your limbs — and this weakness tends to be worse in the morning and gets better with rest, but worse with continued activity. - You (or your le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06298565 · argenx Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2034
🇦🇹 AT🇧🇪 BE🇩🇪 DE🇮🇹 IT🇪🇸 ES🇺🇸 US

"Who might be able to join this trial: - You have been diagnosed with a condition called generalized Myasthenia Gravis (gMG) and are about to start, or have just begun your first cycle of, a treatment called efgartigimod (a commercially available medication). - Alternatively, you have been diagnosed with generalized My...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06299748 · argenx Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2033
🇩🇪 DE🇮🇹 IT🇪🇸 ES🇺🇸 US

"Who might be able to join this trial: - You are a woman who was exposed to the medication efgartigimod or efgartigimod PH20 SC (injected under the skin) at any point during pregnancy, or within 25 days before becoming pregnant. - You are a woman who was exposed to efgartigimod or efgartigimod PH20 SC while breastfeedi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06342544 · Fondation Ophtalmologique Adolphe de Rothschild Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with ocular myasthenia gravis (a condition affecting eye muscles) within the last 6 months - Your diagnosis was confirmed either by a specialist doctor observing typical symptoms, a positive blood test for certain ant...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06371040 · Ting Chang, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old - You are willing and able to follow the study plan, complete all required assessments, and attend follow-up visits - You have been diagnosed with myasthenia gravis (MG) with typical symptoms, and your blood tests have shown positive MG-re...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06392386 · argenx Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 30 September 2026
🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇳🇱 NL +5 more

**Who might be able to join this trial:** - You (or your child's legal guardian) must be able to understand the study requirements and sign a consent form agreeing to take part - The participant must be between 2 and 17 years old at the time of joining the study - The participant must have been diagnosed with generalis...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06414954 · NMD Pharma A/S Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇬🇪 GE🇮🇹 IT🇳🇱 NL🇵🇱 PL🇷🇸 RS +2 more

**Who might be able to join this trial:** - You are a man or woman aged 18 or older at the time of signing the consent form - You have been diagnosed with Myasthenia Gravis (MG) at a moderate to severe level (classified as MGFA class II, III, or IV) - You have had a blood test that confirmed the presence of specific an...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06447597 · Shanghai Jiaolian Drug Research and Development Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You have been diagnosed with generalized myasthenia gravis (a condition that causes muscle weakness throughout the body) - A blood test taken during the screening period shows that you are po...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06455709 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a widespread (generalized) form of Myasthenia Gravis that is caused by a specific type of antibody called anti-AChR - Your doctor has determined that you need treatment with a type of medication called a complement i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06491238 · HealthPartners Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and sign a consent form agreeing to take part in the study - You are between 18 and 80 years old - You have been diagnosed with generalized Myasthenia Gravis (MG), meaning MG that affects muscles across your body - You have been on the same MG medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06587867 · University Health Network, Toronto Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2025
🇨🇦 CA

**Who might be able to join this trial:** - You must be willing and able to sign a consent form, follow the study's requirements, complete all assessments, and attend follow-up visits. - You must be 18 years of age or older (male or female). - You must have been diagnosed with a specific type of myasthenia gravis (MG)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06607627 · Alexion Pharmaceuticals, Inc. Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 15 December 2026
🇧🇷 BR🇯🇵 JP🇵🇱 PL🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - (USA only) You must be between 12 and 17 years old at the time of signing the consent form - (Outside USA) You must be between 6 and 17 years old at the time of signing the consent form - (USA only) You must have received a meningococcal vaccine covering strains A, B, C, W,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06617741 · Myasthenia Gravis Foundation of America Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 September 2029
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with Myasthenia Gravis (MG), a condition that causes muscle weakness Who may not be able to join: - You are under 18 years of age - You have been incorrectly diagnosed with Myasthenia Gravis (MG), meaning the diagnosis w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06626919 · Arcellx, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You must have a moderate to severe form of Myasthenia Gravis (MG), classified at a specific level of severity (Grades 2–4A on a medical scale used to measure MG — confirm with trial site) - Your MG must currently be active and you must...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06685055 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 July 2026
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years old or older. - You have been diagnosed with a specific type of Myasthenia Gravis (a muscle weakness disease) that affects multiple parts of the body and has tested positive for a particular antibody called anti-AChR. - Your doctor has determined that you nee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06688435 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 65 years old. - You have been diagnosed with generalized myasthenia gravis (MG), a muscle weakness condition, at a moderate to severe level (classified as MGFA grade II–IV). - Your myasthenia gravis is considered "refractory," meaning it has not responded w...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06704269 · Novartis Pharmaceuticals Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 26 October 2029
🇫🇷 FR🇯🇵 JP🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with generalized myasthenia gravis (a muscle weakness condition), confirmed by blood tests showing specific antibodies (AChR or MuSK), plus at least one additional test or treatment response supporting the diagnosis. - Your myasthenia gravis is classi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06743490 · Leiden University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 August 2026
🇳🇱 NL

Who might be able to join this trial: - You are 18 years old or older - You are able to understand what the study involves and are willing to sign a consent form **If you have Myasthenia Gravis (MG):** - You have been formally diagnosed with myasthenia gravis (either affecting only the eyes, or more widespread), class...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06754020 · Yi Ting Yeh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 January 2027
🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with myasthenia gravis (a muscle weakness condition) by a doctor. - You are able to understand and communicate in Mandarin or Taiwanese. - You are mentally alert and have not been diagnosed with a psychiatric (mental health) disorder. - You are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06765161 · Clinique Neuro-Outaouais Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 6 January 2027
🇨🇦 CA

**Who might be able to join this trial:** - You are willing and able to sign a consent form to take part in the study. - You are between 18 and 80 years old. - You have been diagnosed with Myasthenia Gravis and have tested positive for acetylcholine receptor antibodies. - Your condition has been stable for at least 4 m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06799247 · Cartesian Therapeutics Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 30 November 2026
🇨🇦 CA🇮🇹 IT🇵🇱 PL🇷🇸 RS🇪🇸 ES Turkey (Türkiye)🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old. - People who have been diagnosed with generalized myasthenia gravis (a condition where the immune system affects muscle control) at a moderate to severe level, based on a standard medical grading scale (grades 2–4), as assessed at the time of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06815133 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with myasthenia gravis (a condition that affects muscle weakness and nerve-muscle communication) and have a specific antibody in your blood called anti-AChR antibody - You are currently being treated with a medicine called Zilucoplan Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06860633 · University of Colorado, Denver Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and have been diagnosed with generalized Myasthenia Gravis (MG), a condition where the immune system attacks the connection between nerves and muscles, confirmed by blood tests showing specific antibodies - Your MG diagnosis has been supporte...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06866483 · ZS Associates Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇺🇸 US

Who might be able to join this trial: - You must live in one of the 50 US states at the time you sign up (not a US territory) - You must be at least 18 years old in most states, at least 19 years old if you live in Nebraska or Alabama, or at least 21 years old if you live in Mississippi - You must have an active email...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06866652 · Institut de Myologie, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been officially diagnosed with autoimmune myasthenia gravis (MG) - You experience shortness of breath during everyday activities, rated as a 1 or 2 out of 3 on a specific MG breathing scale (confirm with trial site) - You are willing a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06879210 · Yi Ting Yeh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2026
🇹🇼 TW

Who might be able to join this trial: - You have been diagnosed with myasthenia gravis by a doctor. - You are 20 years old or older. - You are able to use a smartphone. Who may not be able to join: - You have not been diagnosed with myasthenia gravis. - You do not use a smartphone or tablet. - You leave or drop out of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06881173 · Cheng, yu-ting Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 June 2025
🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with ocular myasthenia (a condition affecting the muscles around the eyes) by a doctor - You are only taking one specific Western medicine tablet called Mestinon (pyridostigmine bromide) by mouth for this condition - You are over 20 years old - You can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06909214 · argenx Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have been diagnosed with generalized Myasthenia Gravis (gMG) at a moderate to severe level (classified as MGFA class II, III, or IV) - Your blood tests show a specific antibody linked to Myasthenia Gr...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06909253 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇵🇱 PL

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with generalised Myasthenia Gravis (a muscle weakness condition), have never previously been treated with a type of drug called a complement inhibitor, and are currently receiving a medicine called ravulizumab through a special...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06940323 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - You are pregnant or thinking about becoming pregnant - You are a woman between 18 and 64 years old - You have been diagnosed with one of the following conditions: Clinically Isolated Syndrome (CIS) or Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Inflam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967480 · Alexion Pharmaceuticals, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Myasthenia Gravis (MG), confirmed by a blood test showing specific antibodies (anti-AChR antibodies) - You also had at least one of the following: an abnormal nerve test (such as single-fibre EMG or repetitive nerve stimulation), a positive "edro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06987539 · Amgen Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 13 March 2030
🇫🇷 FR🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - A parent or legal guardian has given permission for the child to take part, and the child has also agreed to join (where required by local rules). - The participant is between 2 and 17 years old on the day they enroll. - The participant has been diagnosed with generalized My...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07039916 · Immunovant Sciences GmbH Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇦🇷 AR🇨🇿 CZ🇩🇰 DK🇬🇪 GE🇩🇪 DE🇬🇷 GR🇭🇺 HU🇮🇹 IT +6 more

**Who might be able to join this trial:** - You are able to understand what the trial involves, are willing to sign a consent form, and can follow the trial procedures - You have been diagnosed with mild to severe myasthenia gravis (MG), falling into a specific category (Class II, III, or IVa) as assessed at your scree...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07058298 · Daishi Tian Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 13 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written agreement to take part and are willing and able to follow the study procedures (or have a legal representative who has done so on their behalf) - People aged 18 to 75 years old (inclusive), of any sex - People who have been diagnosed with refrac...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07072988 · Centre Hospitalier Universitaire de Nice Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are aged 65 or older - You have been diagnosed with generalized Myasthenia Gravis (a muscle weakness condition), confirmed by medical records, a physical examination, and a blood test showing specific antibodies - Your Myasthenia Gravis falls into a moderate or moderatel...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07146425 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** *For people with Myasthenia Gravis (MG):* - You have been officially diagnosed with myasthenia gravis and are 18 years of age or older. - Your myasthenia gravis has been graded by doctors on a standard scale (called MGFA class I–IV), or your symptoms are currently under contro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07215650 · Candid Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have been diagnosed with Myasthenia Gravis (MG) at a moderate to moderately severe level, and your doctor does not expect you to need breathing support during the study - Your MG symptoms significantl...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07215949 · Miriam Freimer Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a severe flare-up of Myasthenia Gravis (MG), for example having difficulty swallowing, breathing problems that required a hospital stay, or weakness in the neck - Your MG severity falls within a certain range on a standard medical scale (MGFA cla...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07217587 · Janssen Research & Development, LLC Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 28 September 2027
🇮🇱 IL🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** - You are in generally stable health, based on a physical exam, blood tests, heart tracing (ECG), and medical history done at the screening visit. - You have been diagnosed with myasthenia gravis (MG) that affects muscles throughout your body (not just your eyes), and your con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07221838 · Alexion Pharmaceuticals, Inc. Phase 4 · 4 countries Recruiting
Recruiting Phase 4 Est. completion 27 August 2027
🇩🇪 DE🇮🇹 IT🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - You are over 18 years old, either male or female - You have been diagnosed with a condition called generalized Myasthenia Gravis (gMG) - You are already receiving a medication called ravulizumab as part of your treatment - You have been taking oral corticosteroids (steroid tablet...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07246564 · UCB Biopharma SRL Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form - You have been diagnosed with generalized myasthenia gravis (a muscle weakness condition that affects the whole body, not just the eyes) - Your medical records show a positive test for specific ant...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07247279 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇷🇺 RU

Who might be able to join this trial: - You are 18 years of age or older and have been diagnosed with a widespread form of Myasthenia Gravis (a muscle weakness condition) that has been confirmed through a specific blood test showing certain antibodies (called AChR antibodies). - You are willing and able to sign and dat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07249632 · RemeGen Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study. - You are between 12 and 80 years old (male or female). - You weigh at least 30 kg (about 66 pounds). - You have been diagnosed with Myasthenia Gravis (MG) with symptoms that match the disease. - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07250750 · ImmunAbs Inc. Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇧🇬 BG🇮🇹 IT🇵🇱 PL🇷🇸 RS🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You are able and willing to sign a consent form agreeing to take part in the study - You are willing to be tested for genetic muscle diseases - You are 18 years of age or older, but younger than 75 - You have been diagnosed with Myasthenia Gravis (MG) - You have been on a ste...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07284420 · argenx Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 7 March 2028
🇧🇪 BE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Your blood tests show a specific antibody called an "acetylcholine receptor antibody" (AChR-Ab), which is linked to myasthenia gravis - You have been diagnosed with a form of myasthenia gravis called "generalized myasthenia gravis" (gMG) and your condition falls within a cert...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07294170 · argenx Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 7 March 2028
🇧🇪 BE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You are at least 18 years old and meet the legal age requirement for joining a clinical study in your country - You have been diagnosed with Myasthenia Gravis (MG) with symptoms that a doctor has confirmed are consistent with the condition - If you are already taking medication f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07337785 · Tongji Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** **General criteria (all participants):** - People who are willing to take part and sign a consent form agreeing to participate. - People aged 18 to 70 years old, of any gender. - People whose liver function test results are within an acceptable range (specific blood test value...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07411963 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with generalized Myasthenia Gravis (a muscle weakness condition), confirmed by medical records, a physical examination, and a specific blood test showing certain antibodies (AChR-Abs) - You have received more than on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07413835 · The Affiliated Hospital of Xuzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any gender) - You have been diagnosed with generalized myasthenia gravis (MG) — a condition that causes muscle weakness — and your blood tests show specific antibodies linked to this disease (AchR or MuSK antibodies) - Your diagnosis has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07463521 · UCB Biopharma SRL Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old at the time you sign the consent form. - You have been diagnosed with Ocular Myasthenia Gravis (a condition affecting the muscles of the eyes and eyelids), with weakness only in the eye area — all other muscles in your face, throat, and limb...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07470151 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form (either themselves or through a legal guardian) - People aged 18 to 70 years old at the time of signing the consent form, of any gender - People whose blood tests at screening show certain markers on their B cells (CD19 positive)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07570589 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with Myasthenia Gravis (MG), confirmed by a doctor's examination and blood tests showing specific antibodies (anti-AChR or anti-MuSK) - Your MG affects more than just your eyes and falls into a moderate-to-severe catego...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07595653 · argenx Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are at least 18 years old at the time of signing the consent and privacy forms - You have been officially diagnosed with generalized Myasthenia Gravis (a muscle weakness condition that affects the whole body) - Your blood tests have shown that you have a specific antibody...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07596901 · Aurinia Pharmaceuticals Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 March 2029
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 85 years old - You have been diagnosed with generalized Myasthenia Gravis (a muscle weakness condition) that falls within a moderate to severe range of severity, known as MGFA Class II-IV (confirm with trial site) - There may be additional requirements set...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07647510 · Dianthus Therapeutics Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent before any study activities begin - People who weigh between 40 and 130 kg at the time of screening - People diagnosed with generalised myasthenia gravis (a muscle weakness condition), confirmed by a specific antibody test (called AChR a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07673627 · argenx Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a specific antibody in their blood called an anti-acetylcholine receptor antibody (a marker found in a common form of myasthenia gravis). - People who have been formally diagnosed with generalised myasthenia gravis (a muscle weakness condition) and whose dise...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07673744 · TG Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Myasthenia Gravis (MG). - You are eligible to receive the study drug efgartigimod based on your country's approved guidelines, confirmed by a blood test at the start of the study. - Your MG symptoms are measured using a specific scoring system (MG-ADL...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07717281 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇮🇹 IT

Who might be able to join this trial: **For people with Myasthenia Gravis (MG):** - Adults aged 18 or older - People who have been diagnosed with myasthenia gravis based on recognised international standards, meaning they have fluctuating muscle weakness plus at least one confirming test result (such as a positive res...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Myasthenia Gravis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Myasthenia Alliance Australia (MAA) is the national body, formed by an alliance of state associations including the Australian Myasthenic Association (NSW) and the Myasthenia Gravis Association of Queensland. Other states are supported through the Alliance directly.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.